Abstract:Objective To explore the effects of dialysate calcium concentrations (DCC)on risks of adverse reactions occurred in maintenance hemodialysis patients during dialysis. Methods The subjects were end-stage renal disease (ESRD)patients in stable condition who were treated with maintenance dialysis in the First Affiliated Hospital,Zhejiang University from June to October 2016. According to the DCC,the patients were randomly divided into 3 groups,the 1.25 mmol/L group,the 1.35 mmol/L group,and the 1.50 mmol/L group;the observation time was 12 weeks. The urea clearance index Kt/V,urea reduction rate (URR),mean arterial pressure before and after dialysis,the serum calcium,serum phosphorus,intact parathyroid hormone (iPTH),and alkaline phosphatase (ALP)levels before and after dialysis,and the incidence of muscle spasm,nausea and vomiting,headache,chest tightness,and arrhythmia in hemodialysis patients in the 3 groups were compared. Results A total of 273 patients entered the study,including 159 males and 114 females with ages from 25 to 83 years and average age of (52 ± 9)years. Each of the 1.25 mmol/L,1.35 mmol/L,and 1. 50 mmol/L groups comprised 91 patients. The differences of baseline data in patients in the 3 groups were not statistically significant (P＞0.05). After 12 weeks of hemodialysis,the differences of Kt/V and URR in patients in the 3 groups were not statistically significant (all P＞0.05);the differences of the mean arterial pressures in patients in the 1.25 and 1.35 mmol/L groups [(102 ± 9)and (103 ±11)mmHg,respectively]were not statistically significant (all P ＞0.0.5);the mean arterial pressure in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(120 ± 12) mmHg vs.(103 ± 9)mmHg,P＜0.01]and was higher markedly than that in 1.25 and 1.35 mmol/L groups (all P＜0.01);the serum calcium level in patients in the 1.25 mmol/L group was lower than that before hemodialysis [(1.94 ± 0.31)mmol/L vs.(2.24 ± 0.18)mmol/L,P＜0.01];the serum calcium level in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(2.54 ± 0.18) mmol/L vs.(2.24 ± 0.17)mmol/L,P＜0.01];the iPTH and ALP levels in patients in the 1.25 mmol/L group were higher than those before hemodialysis [(356 ± 68)U vs.(291 ± 49)U,(443 ± 45)U vs. (343 ± 58)U,all P ＜0.01]. During dialysis,the incidence of muscle spasm in patients in the 1.25 mmol/L group was higher than that in the 1.35 mmol/L and 1.50 mmol/L groups [14.28% (13/91)vs. 5.49% (5/91)and 4.39% (4/91),all P ＜0.05];the incidence of headache in patients in the 1.50 mmol/L group was higher than that in the 1.25 mmol/L and 1.35 mmol/L groups [14.28% (13/91)vs. 3.30% (3/91)and 5.49% (5/91),P ＝0.01 and P ＜0.05]. The differences in incidences of chest tightness,arrhythmia,nausea and vomiting were not statistically significant (all P＞0.05). Conclusion The dialysate with calcium concentration of 1.35 mmol/L may reduce the incidence of muscle spasm,does not increase the incidence of hypertension and headache,and effectively reduce the risk of adverse reactions in maintenance hemodialysis patients,while ensuring the adequacy of dialysis.

Mathematical finance : basic models and unsolved problems

The effect of dietary phosphorus load and food matrix on postprandial serum phosphate in hemodialysis patients: a pilot study

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.

Journal of Pharmaceutical Negative Results ¦ Volume 13 ¦ Special Issue 9 ¦ 2022 1734 PHOSPHATE BINDERS AS A SUPPLEMENT-ASSESSMENT OF KNOWLEDGE, ATTITUDE AND PRACTICE AMONG ESRD PATIENTS ON MAINTENANCE HEMODIALYSIS IN A TERTIARY CARE TEACHING HOSPITAL IN S

Effect of Short-Term Low-Protein Diet Supplemented with Keto Acids on Hyperphosphatemia in Maintenance Hemodialysis Patients

Doctor-led intensive diet education on health-related quality of life in patients with chronic renal failure and hyperphosphatemia

P1576THE EFFECT OF CHANGING DIETARY PHOSPHORUS-PROTEIN RATIO ON NUTRITIONAL STATUS OF HEMODIALYSIS PATIENTS

Phosphate Binders and Targets Over Decades: Do We have it Right Now?

An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles

Randomized Controlled Trial of Dialysate Calcium Concentrations on Risks of Adverse Reactions in Hemodialysis Patients During Dialysis

Effect of Different Phosphate Binders on Fibroblast Growth Factor 23 Levels in Patients with Chronic Kidney Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials

Effect of Extended Hours Dialysis on Markers of Chronic Kidney Disease-Mineral and Bone Disorder in the ACTIVE Dialysis Study

The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial

The benefit of reduced serum phosphate levels depends on patient characteristics: a nationwide prospective cohort study

Effect of phosphate binder therapy on FGF-23 levels in dialysis patients

Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure

Cross-sectional Study of Calcium Phosphate Product and Intact Parathyroid Hormone Levels in Predialysis and Postdialysis Patients with Stage 5 Chronic Kidney Disease

Effect of a plant protein‐rich diet on postprandial phosphate metabolism in healthy adult men: a randomised controlled trial

Nutrition, Phosphorus, and Keto-Analogues in Hemodialysis Patients: A Chinese Perspective

Oral phosphate binders and incident osteoporotic fracture in patients on dialysis

Association of adequate dietary phosphate restriction education and phosphorus management in maintenance hemodialysis patients